Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)

Exclusion criteria

• ✕. Any investigational product, systemic anticancer therapy, or radiation therapy within 21 days
• ✕. Antibodies or anticancer vaccines within 60 days
• ✕. Mifepristone or other GR antagonists within 5 half-lives of these medications
• ✕. Adrenostatic medications within 5 half-lives of these medications
• ✕. Unstable angina pectoris, angioplasty, cardiac stenting, or myocardial infarction 3 months before study entry.
• ✕. Active infection that requires parenteral antibiotics.
• ✕. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.